Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes

NCT07224321 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.

NCT NCT07224321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes
Lead sponsor
Mannkind Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
February 4, 2026
Completion date
September 30, 2027
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus